Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. M. T. A. van Durme, K. M. C. Verhamme, G. R. Van Pottelberge, A. Hofman, G. F. Joos, B. H. Stricker, G. G. Brusselle (Ghent, Belgium; Rotterdam, Netherlands). C-reactive protein levels and the risk of COPD in a general population: the Rotterdam study. Eur Respir J 2007; 30: Suppl. 51, 2139

Member's Comments

No comment yet.

Related content which might interest you: C-reactive protein serum levels, genotypes and the risk of COPD. The Rotterdam study Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD Year: 2008 LSC - 2021 - The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 PP302 – The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension Source: ERS Lung Science Conference 2021 Year: 2021 The study on the association of serum C-reactive protein level with the risk of lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis Source: Eur Respir Rev 2017; 26: 160070 Year: 2017 Is there a relationship between severity of COPD and C-reactive protein (CRP) levels? Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 High-sensitive C-reactive protein is associated with reduced lung function in young adults Source: Eur Respir J 2009; 33: 382-388 Year: 2009 The lifetime risk of developing COPD. The Rotterdam study Source: Annual Congress 2008 - Environmental risk factors for respiratory symptoms and COPD Year: 2008 Variations in C-reactive protein gene and COPD: tagging SNPs analysis in case-control study Source: Annual Congress 2007 - Acute and chronic lung injury and its repair: novel molecular insight Year: 2007 C-reactive protein (CRP) as a risk marker in COPD patients with ischaemic heart disease Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 Value of neutrophil-to-lymphocyte ratio, procalcitonin, and C-reactive protein in help to predict weaning outcome: a prospective, observational cohort study Source: International Congress 2017 – COPD and weaning Year: 2017 C-reactive protein level and risk of developing COPD: The Kangbuk Samsung Cohort Study Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. Source: International Congress 2017 – COPD biomarkers Year: 2017 COPD, asthma and C-reactive protein Source: Eur Respir J 2006; 27: 874-876 Year: 2006 Health effects of self-reported risk factors and estimated PM10 levels: a cross-sectional study. Source: International Congress 2019 – Epidemiology, genetics, air pollution and sleep Year: 2019 The effect of the indicated use of ß-blockers on the risk of COPD exacerbations: the Rotterdam Study Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Mortality and prognostic factors in a cohort of COPD patients (EXACO study) Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010 Association between C-reactive protein levels and outcome in acute lung injury in children Source: Annual Congress 2011 - Issues in paediatric and neonatal intensive care Year: 2011 Quantifying comorbidity in individuals with COPD: a population study Source: Eur Respir J 2015; 45: 51-59 Year: 2015 The Rotterdam study: why fall in COPD? Source: Eur Respir J 2015; 46: 1530-1531 Year: 2015